Navigator Medicines Emerges With $100m, Autoimmune Candidate
Backed by Forbion and RA Capital, Navigator will focus on novel OX40-targeted therapies for autoimmune diseases, with a clinical candidate in-licensed from IMBiologics.
Backed by Forbion and RA Capital, Navigator will focus on novel OX40-targeted therapies for autoimmune diseases, with a clinical candidate in-licensed from IMBiologics.